# DARPA Launches $73 Million RAPIID Program to Develop Synthetic Blood US military funds shelf-stable blood components to prevent battlefield hemorrhage fatalities - **Source:** [MIT Technology Review](https://www.technologyreview.com) - **Published:** 2026-10-14 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/23faff04-c4aa-4d97-bb11-90a3de9adb68 ## Lethal Battlefield Blood Logistics In 2007, a dual-rotor casualty evacuation helicopter named Morphine 1-2 was shot down during a daylight blood delivery mission near Karmah, Iraq, killing all seven crew members. This tragedy underscored the deadly vulnerabilities of ferrying perishable biological supplies across combat zones. ## Critical Resuscitation Time Window Hemorrhage causes roughly 90% of preventable battlefield deaths and remains a leading cause of maternal mortality worldwide. Combat data from Afghanistan indicates that severely injured patients who require transfusions must receive blood within 36 minutes before survival rates drop precipitously. ## Storage Limits Fuel Shortages Whole blood lasts just 35 days under refrigeration, while platelets degrade within a single week at room temperature. Frozen red cells and plasma spoil rapidly once thawed, leaving military units and civilian trauma centers facing critical shortages during unpredictable mass casualty emergencies. ## RAPIID Program Targets 2029 DARPA program manager Robert Murray is leading RAPIID, a $73 million initiative following the $47.5 million FSHARP project. The program aims to deploy freeze-dried, shelf-stable versions of plasma, platelets, and red blood cells in field-ready bags by 2029. ## Evolution of Freeze-Dried Plasma Freeze-dried plasma was used extensively during World War II but was later abandoned due to hepatitis transmission risks from infected donors. Improved screening and drying techniques enabled the US military to rebuild production capacity, securing FDA emergency authorization for modern formulations. ## Past Oxygen Carrier Failures Early hemoglobin-based oxygen carriers caused severe side effects because naked hemoglobin rapidly scavenges nitric oxide, constricting blood vessels. Clinical trials of HemAssist were halted in 1998 after 24 of 52 recipients died, reflecting elevated heart attack and mortality risks. ## Lab-Grown Blood Economic Bottlenecks DARPA previously explored pharming red blood cells from umbilical-cord stem cells starting in 2008. The agency abandoned the initiative after failing to bring manufacturing costs below tens of thousands of dollars per unit, while the resulting cells still required strict cold-chain refrigeration. ## Vulnerability of Pacific Supply Hubs Strategic shifts toward potential high-intensity Pacific conflicts exposed logistical chokepoints, such as an Okinawa blood bank supporting thousands of personnel across USPACOM. Concentrated storage sites adjacent to communication nodes remain highly vulnerable to targeted missile strikes during coordinated military offensives. ## ErythroMer Mimics Cellular Chemistry Biotech startup KaloCyte is developing ErythroMer, which encapsulates donor hemoglobin inside lipid nanoparticles. A specialized lipid called KC-1003 senses physiological pH changes, directing hemoglobin to capture oxygen in the lungs and efficiently release it within oxygen-depleted, acidic tissues. ## Long Shelf-Life Resuscitation Design Lyophilized into a scarlet powder, ErythroMer remains stable at room temperature for two years. In animal studies involving 70% blood loss, the product restored blood pressure and tissue oxygenation without triggering the dangerous vasoconstriction observed in older hemoglobin-based therapeutic candidates. ## SynthoPlate Engineers Artificial Clotting Case Western Reserve University researchers developed SynthoPlate, a lipid nanoparticle engineered with specific surface peptides. These biological attachments bind to von Willebrand factor, adhere to exposed collagen scaffolds, and mimic fibrinogen to recruit natural platelets at vascular injury sites. ## Modular Field Transfusion Architecture DARPA envisions a multi-chambered, field-rehydratable kit containing separate dried plasma, synthetic platelets, and artificial red cells. Overcoming hemoglobin sourcing limitations and aligning parallel clinical trials with the FDA will determine whether synthetic blood can successfully eliminate battlefield mortality. ## Sources covering this story - https://www.technologyreview.com/2026/10/14/1145807/us-military-race-to-make-fake-blood/ — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._